Merck, Moderna Phase 3 Combo Cuts Melanoma Recurrence Risk 42%
Merck said intismeran (V940) plus KEYTRUDA reduced recurrence or death risk by 42% and distant metastasis or death risk by 38% versus KEYTRUDA alone in resected stage IIB–IV melanoma. Overall survival data are not mature; the companies are engaging regulators.